🇺🇸 FDA
Pipeline program

Psilocybin

COMP 201

Phase 2 small_molecule completed

Quick answer

Psilocybin for Post Traumatic Stress Disorder is a Phase 2 program (small_molecule) at Compass Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Compass Therapeutics
Indication
Post Traumatic Stress Disorder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials